True Wealth Design
ALNY icon

True Wealth Design’s Alnylam Pharmaceuticals ALNY Stock Holding History

True Wealth Design’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$43.9K Buy
178
+83
+87% +$21.1K 0.01% 554
2026
Q2 		$28.6K Buy
95
+19
+25% +$5.73K 0.01% 692
2026
Q1 		$25.1K Sell
76
-79
-51% -$26.9K 0.01% 624
2025
Q4 		$61.5K Sell
155
-73
-32% -$32.3K 0.02% 281
2025
Q3 		$104K Buy
228
+214
+1,529% +$87.1K 0.03% 158
2025
Q2 		$4.6K Sell
14
-285
-95% -$78.9K ﹤0.01% 838
2025
Q1 		$80.8K Buy
299
+147
+97% +$37.8K 0.03% 120
2024
Q4 		$35.8K Sell
152
-2
-1% -$526 0.01% 231
2024
Q3 		$42.4K Buy
154
+153
+15,300% +$39.8K 0.02% 166
2024
Q2 		$243 Sell
1
-1
-50% -$158 ﹤0.01% 734
2024
Q1 		$299 Buy
2
+1
+100% +$167 ﹤0.01% 713
2023
Q4 		$192 Hold
1
– – ﹤0.01% 682
2023
Q3 		$178 Hold
1
– – ﹤0.01% 662
2023
Q2 		$190 Hold
1
– – ﹤0.01% 657
2023
Q1 		$201 Hold
1
– – ﹤0.01% 730
2022
Q4 		$238 Buy
+1
New +$213 ﹤0.01% 637

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

True Wealth Design's ALNY Position: Q3 2026 in Review

True Wealth Design increased its Alnylam Pharmaceuticals (ALNY) stake by 87% in Q3 2026, buying an estimated $21.1K and bringing the position to 178 shares worth $43.9K. The position accounts for 0.01% of the portfolio, ranked #554.

True Wealth Design first reported a position in ALNY in Q4 2022 and has held it in 16 quarters since. The position peaked at $104K in Q3 2025. 403 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • True Wealth Design held 178 shares of Alnylam Pharmaceuticals worth $43.9K as of Q3 2026.
  • True Wealth Design bought 83 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $21.1K.
  • Alnylam Pharmaceuticals made up 0.01% of True Wealth Design's portfolio in Q3 2026, its #554 holding.
  • True Wealth Design first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
  • True Wealth Design's Alnylam Pharmaceuticals position peaked at $104K in Q3 2025.
  • 403 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.